TW200909446A - Anti-IGF antibodies - Google Patents

Anti-IGF antibodies Download PDF

Info

Publication number
TW200909446A
TW200909446A TW097122727A TW97122727A TW200909446A TW 200909446 A TW200909446 A TW 200909446A TW 097122727 A TW097122727 A TW 097122727A TW 97122727 A TW97122727 A TW 97122727A TW 200909446 A TW200909446 A TW 200909446A
Authority
TW
Taiwan
Prior art keywords
igf
cancer
antibody
antibody molecule
human antibody
Prior art date
Application number
TW097122727A
Other languages
English (en)
Chinese (zh)
Inventor
Paul Adam
Elinborg Ostermann
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of TW200909446A publication Critical patent/TW200909446A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
TW097122727A 2007-06-19 2008-06-18 Anti-IGF antibodies TW200909446A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP07110587 2007-06-19

Publications (1)

Publication Number Publication Date
TW200909446A true TW200909446A (en) 2009-03-01

Family

ID=39154657

Family Applications (1)

Application Number Title Priority Date Filing Date
TW097122727A TW200909446A (en) 2007-06-19 2008-06-18 Anti-IGF antibodies

Country Status (10)

Country Link
US (1) US8580254B2 (enExample)
EP (1) EP2220119B1 (enExample)
JP (1) JP2010531140A (enExample)
AR (1) AR067046A1 (enExample)
CA (1) CA2689521A1 (enExample)
CL (1) CL2008001814A1 (enExample)
PE (1) PE20090368A1 (enExample)
TW (1) TW200909446A (enExample)
UY (1) UY31160A1 (enExample)
WO (1) WO2008155387A2 (enExample)

Families Citing this family (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE428421T1 (de) 2004-09-17 2009-05-15 Eisai R&D Man Co Ltd Medizinische zusammensetzung mit verbesserter stabilität und reduzierten gelierungseigenschaften
EP1925676A4 (en) 2005-08-02 2010-11-10 Eisai R&D Man Co Ltd TEST METHOD FOR THE EFFECT OF A VASCULARIZATION INHIBITOR
WO2007136103A1 (ja) 2006-05-18 2007-11-29 Eisai R & D Management Co., Ltd. 甲状腺癌に対する抗腫瘍剤
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
CN101848895B (zh) * 2007-11-09 2013-10-23 卫材R&D管理有限公司 血管新生抑制物质和抗肿瘤性铂络合物的组合使用
EP2376116B1 (en) 2008-12-12 2015-12-09 Boehringer Ingelheim International GmbH Anti-igf antibodies
WO2010099139A2 (en) * 2009-02-25 2010-09-02 Osi Pharmaceuticals, Inc. Combination anti-cancer therapy
TW201102068A (en) * 2009-06-02 2011-01-16 Novartis Ag Treatment of ophthalmologic disorders mediated by alpha-carbonic anhydrase isoforms
BR112012003592B8 (pt) 2009-08-19 2021-05-25 Eisai R&D Man Co Ltd composição farmacêutica contendo derivado de quinolina
AU2014256364B2 (en) * 2009-10-07 2016-07-07 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Human domain antibodies against components of the human insulin-like growth factor (IGF) system
EP2486055A4 (en) 2009-10-07 2013-04-17 Us Health HUMAN ANTIBODIES AGAINST COMPONENTS OF THE SYSTEM OF THE HUMAN INSULINARY GROWTH FACTOR (IGF)
BR112012012160B1 (pt) * 2009-11-13 2022-04-26 Amgen, Inc. Material e métodos para tratar ou prevenir doenças associadas ao her-3
EP2382976A1 (en) 2010-04-30 2011-11-02 Hiroshima University Use of pdgf-r inhibitors for the treatment of lymph node metastasis of gastric cancer
CA2802644C (en) * 2010-06-25 2017-02-21 Eisai R & D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
EP2700403B1 (en) 2011-04-18 2015-11-25 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
WO2012166899A2 (en) 2011-06-03 2012-12-06 Eisai R&D Management Co., Ltd. Biomarkers for predicting and assessing responsiveness of thyroid and kidney cancer subjects to lenvatinib compounds
AU2013364953A1 (en) 2012-12-21 2015-04-30 Eisai R&D Management Co., Ltd. Amorphous form of quinoline derivative, and method for producing same
US20140255413A1 (en) 2013-03-07 2014-09-11 Boehringer Ingelheim International Gmbh Combination therapy for neoplasia treatment
CN105264380B (zh) 2013-05-14 2017-09-05 卫材R&D管理有限公司 用于预测和评价子宫内膜癌受试者对乐伐替尼化合物响应性的生物标志
US20140378401A1 (en) * 2013-06-21 2014-12-25 Gnt, Llc Ophthalmic Lipophilic and Hydrophilic Drug Delivery Vehicle Formulations
EP3096792B1 (en) * 2014-01-24 2019-09-25 Boehringer Ingelheim International GmbH Cancer treatment using an insulin-like growth factor (igf) receptor antagonist in combination with exemestane and everolimus
EP3131552B1 (en) * 2014-04-16 2020-07-15 Signal Pharmaceuticals, LLC Methods for treating cancer using tor kinase inhibitor combination therapy
CA2957005C (en) 2014-08-28 2021-10-12 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
SG11201706630UA (en) 2015-02-25 2017-09-28 Eisai R&D Man Co Ltd Method for suppressing bitterness of quinoline derivative
WO2016140717A1 (en) 2015-03-04 2016-09-09 Merck Sharp & Dohme Corp. Combination of a pd-1 antagonist and a vegfr/fgfr/ret tyrosine kinase inhibitor for treating cancer
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
JP6553726B2 (ja) 2015-08-20 2019-07-31 エーザイ・アール・アンド・ディー・マネジメント株式会社 腫瘍治療剤
US10624874B2 (en) * 2017-01-10 2020-04-21 Zhejiang Jiachi Development Pharmaceuticals Ltd Lasofoxifene modulation of membrane-initiated estrogen signals and methods for tumor treatment
US12303505B2 (en) 2017-02-08 2025-05-20 Eisai R&D Management Co., Ltd. Tumor-treating pharmaceutical composition
BR112019023064A2 (pt) 2017-05-16 2020-06-09 Eisai R&D Man Co Ltd tratamento de carcinoma hepatocelular

Family Cites Families (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) * 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4342566A (en) * 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
DE3486216T2 (de) 1983-04-25 1994-02-17 Chiron Corp Hybrid-DNS-Synthesis von reifen insulinähnlichen Wachstumsfaktoren.
WO1985000831A1 (en) 1983-08-10 1985-02-28 Amgen Microbial expression of insulin-like growth factor
AU1232188A (en) 1987-05-29 1988-12-01 Mallinckrodt, Inc. Novel pair of monoclonal antibodies to insulin-like growth factor i permits immunometric assay for igf-i
WO1989011297A1 (en) 1988-05-27 1989-11-30 Centocor, Inc. Freeze-dried formulation for antibody products
JPH03501487A (ja) 1988-06-30 1991-04-04 シティ・オブ・ホープ インシュリン模倣物およびインシュリンリセプター結合部位ペプチド
CA2058041A1 (en) 1990-06-27 1991-12-28 Katsuichi Sakano Anti-igf-ii monoclonal antibody
DE69420137T2 (de) 1993-06-03 1999-12-23 Therapeutic Antibodies, Inc. Herstellung von antikörperfragmenten
EP0700994A1 (en) 1994-03-23 1996-03-13 Japan Clinical Laboratories Anti-igf-i monoclonal antibody
US6685940B2 (en) * 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US5916771A (en) * 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6991790B1 (en) * 1997-06-13 2006-01-31 Genentech, Inc. Antibody formulation
GB9722131D0 (en) * 1997-10-20 1997-12-17 Medical Res Council Method
JP2001525339A (ja) 1997-11-27 2001-12-11 コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼーション Ｉｇｆ受容体に対するアゴニストおよびアンタゴニストの設計方法
IL145941A (en) * 1999-04-28 2007-08-19 Univ Texas Compositions and methods for cancer treatment by selectively inhibiting vegf
PA8535501A1 (es) * 2001-01-05 2003-07-28 Pfizer Anticuerpos contra el receptor del factor de crecimiento similar a insulina
CN101684158A (zh) 2001-01-17 2010-03-31 特鲁比昂药品公司 结合域-免疫球蛋白融合蛋白
AU2002319402B2 (en) 2001-06-28 2008-09-11 Domantis Limited Dual-specific ligand and its use
US20050214857A1 (en) 2001-12-11 2005-09-29 Algonomics N.V. Method for displaying loops from immunoglobulin domains in different contexts
CA2473039C (fr) 2002-01-18 2014-09-23 Pierre Fabre Medicament Nouveaux anticorps anti-igf-ir et leurs applications
JP2003310275A (ja) 2002-04-30 2003-11-05 Kyowa Hakko Kogyo Co Ltd ヒトインスリン様成長因子に対する遺伝子組換え抗体
US7438911B2 (en) * 2002-04-30 2008-10-21 Kyowa Hakko Kogyo Co., Ltd. Antibody against human insulin-like growth factor
NZ536475A (en) 2002-05-24 2008-06-30 Schering Corp Neutralizing human anti-igfr antibody
US7538195B2 (en) 2002-06-14 2009-05-26 Immunogen Inc. Anti-IGF-I receptor antibody
US8034904B2 (en) 2002-06-14 2011-10-11 Immunogen Inc. Anti-IGF-I receptor antibody
EP1600459A3 (en) 2002-06-28 2005-12-07 Domantis Limited Ligand
JP2006523090A (ja) 2002-12-27 2006-10-12 ドマンティス リミテッド リガンドに、そしてリガンド受容体に特異的な二重特異性単一ドメイン抗体
CA2514231A1 (en) 2003-02-13 2004-08-26 Pfizer Products Inc. Uses of anti-insulin-like growth factor i receptor antibodies
MXPA05009837A (es) 2003-03-14 2005-12-05 Pharmacia Corp Anticuerpos para el receptor del factor de crecimiento tipo insulina-i, para el tratamiento de canceres.
CA2524305C (en) 2003-05-01 2015-12-08 Imclone Systems Incorporated Fully human antibodies directed against the human insulin-like growth factor-1 receptor
US7579157B2 (en) 2003-07-10 2009-08-25 Hoffmann-La Roche Inc. Antibody selection method against IGF-IR
WO2005018671A1 (ja) 2003-08-21 2005-03-03 Kyowa Hakko Kogyo Co., Ltd. 癌転移阻害剤
WO2005028515A1 (ja) 2003-09-24 2005-03-31 Kyowa Hakko Kogyo Co., Ltd. ヒトインスリン様成長因子に対する遺伝子組換え抗体
JPWO2005027970A1 (ja) 2003-09-24 2007-11-15 協和醗酵工業株式会社 癌治療用医薬
WO2005058967A2 (en) 2003-12-16 2005-06-30 Pierre Fabre Medicament Novel anti-insulin/igf-i hybrid receptor or anti-insulin/igf-i hybrid receptor and igf-ir antibodies and uses thereof
RU2342159C2 (ru) 2004-07-16 2008-12-27 Пфайзер Продактс Инк. Комбинированная терапия негематологических злокачественных опухолей с использованием анти-igf-1r-антитела
MY146381A (en) 2004-12-22 2012-08-15 Amgen Inc Compositions and methods relating relating to anti-igf-1 receptor antibodies
EP1888647A2 (en) * 2005-05-24 2008-02-20 MorphoSys AG Generation and profiling of fully human hucal gold®-derived therapeutic antibodies specific for human cd38
FR2888850B1 (fr) 2005-07-22 2013-01-11 Pf Medicament Nouveaux anticorps anti-igf-ir et leurs applications
PL2860192T3 (pl) 2005-10-12 2018-03-30 Morphosys Ag Wytwarzanie i profilowanie w pełni ludzkich, uzyskanych z HuCAL GOLD terapeutycznych przeciwciał swoistych wobec ludzkiego CD38
ATE552853T1 (de) * 2005-12-13 2012-04-15 Medimmune Ltd Proteine die spezifisch insulin-ähnliche wachstumsfaktoren binden, und deren anwendungen
US7612178B2 (en) * 2006-03-28 2009-11-03 Biogen Idec Ma Inc Anti-IGF-1R antibodies and uses thereof
US8071323B2 (en) 2006-04-07 2011-12-06 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Human monoclonal antibodies that bind human insulin like growth factors and their use
US20080014203A1 (en) 2006-04-11 2008-01-17 Silke Hansen Antibodies against insulin-like growth factor I receptor and uses thereof
PT2027470E (pt) 2006-06-02 2013-01-28 Pfizer Prod Inc Ensaio de células tumorais circulantes
US20080112888A1 (en) 2006-06-30 2008-05-15 Schering Corporation Igfbp2 biomarker
WO2008079324A1 (en) 2006-12-21 2008-07-03 Boston Biomedical Research Institute Immunological modulation of insulin-like growth factor 1 for cancer prevention/treatment and prolonging longevity
AR064464A1 (es) 2006-12-22 2009-04-01 Genentech Inc Anticuerpos anti - receptor del factor de crecimiento insulinico
GB0702888D0 (en) 2007-02-14 2007-03-28 Glaxo Group Ltd Novel Antibodies
AU2008223541B2 (en) 2007-03-02 2012-04-05 Amgen Inc. Methods and compositions for treating tumor diseases
WO2008115470A2 (en) 2007-03-16 2008-09-25 East Carolina University Hox-gene expression as a biomarker for igf-1r therapeutics
MX2009010179A (es) 2007-03-22 2010-03-15 Imclone Llc Formulaciones estables de anticuerpo.
EP2145021A2 (en) 2007-05-17 2010-01-20 Bristol-Myers Squibb Company Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators
US8178091B2 (en) * 2007-05-21 2012-05-15 University Of Washington Compositions and methods for the treatment of respiratory disorders
WO2008152422A2 (en) 2007-06-12 2008-12-18 Astrazeneca Ab Binding proteins specific for insulin-like growth factors and uses thereof-909
PE20090368A1 (es) 2007-06-19 2009-04-28 Boehringer Ingelheim Int Anticuerpos anti-igf
WO2009005673A1 (en) 2007-06-28 2009-01-08 Schering Corporation Anti-igf1r
US20110052667A1 (en) 2007-06-28 2011-03-03 Sylgen Laboratories, Inc. Compositions and methods for inhibiting angiogenesis and tumorigenesis
CA2694990A1 (en) 2007-07-31 2009-02-05 Merck Sharp & Dohme Corp. Igf-1r specific antibodies useful in the detection and diagnosis of cellular proliferative disorders
AU2008281801A1 (en) 2007-08-01 2009-02-05 Glaxo Group Limited Novel antibodies
US8426557B2 (en) 2007-08-03 2013-04-23 Affibody Ab IGF-1R binding polypeptides and their use
ES2453108T3 (es) 2007-08-06 2014-04-04 Orion Genomics, Llc Nuevos polimorfismos de un único nucleótido y combinaciones de polimorfismos nuevos y conocidos para determinar la expresión específica de alelo del gen IGF2
AU2008295506A1 (en) 2007-08-28 2009-03-12 Biogen Idec Ma Inc. Anti-IGF-1R antibodies and uses thereof
JP2010538012A (ja) 2007-08-28 2010-12-09 バイオジェン アイデック マサチューセッツ インコーポレイテッド Ｉｇｆ−１ｒの複数のエピトープに結合する組成物
AU2008302076B2 (en) 2007-09-19 2015-06-11 The Trustees Of Boston University Identification of novel pathways for drug development for lung disease
EP2208066A2 (en) 2007-10-03 2010-07-21 OSI Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
CA2694154A1 (en) 2007-10-03 2009-04-09 Osi Pharmaceuticals, Inc. Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
EP2247757A2 (en) 2007-12-18 2010-11-10 Schering Corporation Biomarkers for sensitivity to anti-igf1r therapy
US20090258365A1 (en) 2008-03-25 2009-10-15 Terstappen Leon W M M METHOD FOR DETECTING IGF1R/Chr 15 in CIRCULATING TUMOR CELLS USING FISH
US20090291088A1 (en) 2008-04-11 2009-11-26 Biogen Idec Ma Inc. Therapeutic combinations of anti-igf-1r antibodies and other compounds
CA2722992A1 (en) 2008-05-05 2009-11-12 Schering Corporation Sequential administration of chemotherapeutic agents for treatment of cancer
JP5734180B2 (ja) 2008-05-09 2015-06-17 ダイアックス コーポレーション Ｉｇｆ−ｉｉ／ｉｇｆ−ｉｉｅ結合タンパク質
PE20100054A1 (es) 2008-06-03 2010-03-03 Abbott Lab Inmunoglobulina con dominio variable dual
PE20110926A1 (es) 2008-09-26 2011-12-29 Roche Glycart Ag Anticuerpos biespecificos anti-egfr/anti-igf-1r
EP2342318A1 (en) 2008-09-26 2011-07-13 Schering Corporation High titer antibody production
WO2010045315A1 (en) 2008-10-14 2010-04-22 Dyax Corp. Use of igf-ii/igf-iie binding for the treatment and prevention of systemic sclerosis associated pulmonary fibrosis
EP2350317A4 (en) 2008-10-20 2012-06-27 Univ Colorado Regents BIOLOGICAL MARKERS FOR PREDICTING THE ANTICIPATE RESPONSE TO INSULINARY GROWTH FACTOR 1 RECEPTOR KINASE INHIBITORS
EP2356148A2 (en) 2008-11-10 2011-08-17 Novartis AG Antibodies to modified human igf-1/e peptides
MX2011005672A (es) 2008-11-28 2011-06-20 Abbott Lab Composiciones de anticuerpo estables y metodos para estabilizar a las mismas.
EP2376116B1 (en) * 2008-12-12 2015-12-09 Boehringer Ingelheim International GmbH Anti-igf antibodies
WO2010069858A1 (en) 2008-12-19 2010-06-24 F. Hoffmann-La Roche Ag Pharmaceutical composition
CA2748119A1 (en) 2008-12-23 2010-07-01 Salk Institute For Biological Studies Method of treating neurodegenerative disease

Also Published As

Publication number Publication date
UY31160A1 (es) 2009-01-30
US20100196395A1 (en) 2010-08-05
PE20090368A1 (es) 2009-04-28
EP2220119A2 (en) 2010-08-25
EP2220119B1 (en) 2013-08-14
CA2689521A1 (en) 2008-12-24
JP2010531140A (ja) 2010-09-24
AR067046A1 (es) 2009-09-30
CL2008001814A1 (es) 2009-09-11
US8580254B2 (en) 2013-11-12
WO2008155387A3 (en) 2009-04-30
WO2008155387A2 (en) 2008-12-24

Similar Documents

Publication Publication Date Title
US11299538B2 (en) Anti-IGF antibodies
EP2220119B1 (en) Anti-igf antibodies that bind to igf-1 and igf-2 but not to insulin
TWI414532B (zh) 抗第１型類胰島素生長因子接受器之抗體及其之使用
US8933202B2 (en) AXL antibodies
JP6661734B2 (ja) 線維芽増殖因子受容体２に対するモノクローナル抗体
CN115340608A (zh) 用于癌症治疗的抗pd-1和抗-lag3抗体
US20150152193A1 (en) Axl antibodies
HK1158933B (en) Anti-igf antibodies
HK1191352A (en) Anti-igf antibodies
HK1191351A (en) Anti-igf antibodies
HK1146415A (en) Binding molecules to the human ox40 receptor